Research Studies
Open, pending, and completed studies
MiraKind has a pipeline of open and pending studies to identify new biomarkers of disease risk, as well as to help determine the best ways to protect the health of individuals with biomarkers of interest, such as the KRAS-variant.
JOIN OUR NEW STUDY
What is the Role of Hormone Replacement Therapy in Breast Cancer Risk?
OPEN STUDIES
Open Study 1
This study will investigate the 'triggers' for an initial cancer diagnosis in KRAS-variant positive individuals.
Open Study 2
This study will investigate 'triggers' for a second cancer diagnosis in KRAS-variant individuals.
Pending STUDIES
The KRAS-variant and Pregnancy Associated Breast Cancer
This is a study to determine if women with the KRAS-variant are more likely to develop pregnancy associated breast cancer, which is breast cancer diagnosed within five years of being pregnant.
The KRAS-variant, endometriosis and ovarian cancer
This is a study to better understand the association between the KRAS-variant, endometriosis and ovarian cancer. The KRAS-variant is the first genetic marker associated with endometriosis, has been shown to be a significant risk factor for ovarian cancer, and endometriosis is a risk for ovarian cancer. If you have endometriosis, please join and help us understand how different management strategies can help prevent ovarian cancer.
Completed Studies
Hormones, the KRAS-variant and Breast Cancer Risk
This study examined the relationship between hormone replacement therapy and other types of hormone exposures and breast cancer risk for women with and without the KRAS-variant. This study is closed for enrollment and analysis is finalized. The paper is ready for submission for publication in a leading medical journal. The study results will be presented at San Antonio Breast Conference.
Questions? Contact us!
